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ABSTRACT
High-dose therapy with autologous hematopoietic cell transplantation (auto-HCT) is frequently used to
improve outcomes in lymphoma. However, small studies suggest a survival disadvantage among obese patients.
Using a retrospective cohort analysis, we studied the outcomes of 4681 patients undergoing auto-HCT for
Hodgkin or non-Hodgkin lymphoma between 1990 and 2000 according to body mass index (BMI). Four groups
categorized by BMI were compared by using Cox proportional hazards regression to adjust for other prog-
nostic factors. A total of 1909 patients were categorized as normal weight (BMI 18-25 kg/m2), 121 as
underweight (BMI <18 kg/m2), 1725 as overweight (BMI >25-30 kg/m2), and 926 as obese (BMI >30 kg/m2)
at the time of HCT. Outcomes evaluated included overall survival, relapse, transplantation-related mortality
(TRM), and lymphoma-free survival. TRM was similar among the normal, overweight, and obese groups; the
underweight group had a higher risk of TRM (relative risk [RR], 2.46; 95% confidence interval [CI], 1.59-3.82;
P < 0.0001) compared with the normal-BMI group. No differences in relapse were noted. Overall mortality
was higher in the underweight group (RR, 1.48; 95% CI, 1.17-1.88; P .001) and lower in the overweight (RR,
0.87; 95% CI, 0.79-0.96; P  .004) and obese (RR, 0.76; 95% CI, 0.67-0.86; P < .0001) groups compared with
the normal-BMI group. In light of our inability to find differences in survival among overweight, obese, and
normal-weight patients, obesity alone should not be viewed as a contraindication to proceeding with auto-
HCT for lymphoma when it is otherwise indicated.
© 2006 American Society for Blood and Marrow Transplantation
KEY WORDS
Body mass index ● Lymphoma ● Autologous HCT ● Mortality
t
o
S
f
[
t
c
B
c
tNTRODUCTION
Obesity is an increasing global health issue [1-3].
rom 1991 to 1998 in the United States, the incidence
f obesity, deﬁned as a body mass index (BMI) of 30
g/m2, escalated by 49% [4]. Estimates for 2001 to
002 indicate that 28% of men and 33% of women are
bese [5]. Obesity is known to increase the risk of a
ariety of common medical conditions, such as car-
iovascular disease [6-8], diabetes mellitus [9], and
ancer [10,11], and contributes to premature death
12]. Additionally, because of the perception that
bese patients experience poorer outcomes, obese pa- p
B&MTients are sometimes denied medical procedures that
therwise would be considered appropriate [13,14].
ome data suggest that physicians’ judgments are af-
ected by negative attitudes toward obese individuals
15-20]. Recently, however, several studies examining
he effect of obesity on surgical outcomes have indi-
ated no excessive morbidity attributable to increased
MI alone after cardiac [21-23], general [14], and
olorectal [24] surgery.
Concurrent with an epidemic of obesity is a con-
inual increase in the incidence of non-Hodgkin lym-
homa (NHL). It is estimated that approximately
541
6
c
s
m
o
i
w
c
o
f
a
c
t
H
p
w
[
c
m
a
o
f
t
l
I
(
v
M
D
m
t
S
M
N
t
t
l
t
p
c
n
b
r
c
n
o
v
o
o
r
t
m
a
c
s
C
c
P
t
P
P
a
l
d
g
d
a
E
k
1
a
1
C
p
a
r
p
b
p
w
w
(
l
S
m
(
w
c
a
t
s
p
L
r
t
ﬁ
o
a
d
L
t
o
W. H. Navarro et al.
51 000 new cases of NHL in the United States oc-
urred in 2003 [25]. Interestingly, recent evidence
uggests that obesity is associated with the develop-
ent of NHL [10,11]. High-dose therapy with autol-
gous hematopoietic cell transplantation (auto-HCT)
mproves long-term disease-free survival in patients
ith refractory or relapsed lymphoma compared with
onventional-dose chemotherapy [26-31]. The effect
f obesity on outcomes and toxicity after auto-HCT
or lymphoma is not known. As early as 1970, Wiernik
nd Serpick [32] identiﬁed obesity as a risk factor for
hemotherapy induction failure and mortality in pa-
ients with acute myelogenous leukemia. Studies of
CT show conﬂicting data about outcomes for obese
atients; some report no difference in overall survival,
hereas others indicate poorer survival (see reviews
33,34]). In contrast, underweight patients are more
onsistently shown to have poorer outcomes than nor-
al-weight patients [35,36].
On the basis of the increasing frequency of obesity
nd lymphoma, it is clear that increasing numbers of
bese individuals with lymphoma will be considered
or auto-HCT. Therefore, we performed a retrospec-
ive study of individuals undergoing auto-HCT for
ymphoma by using the database of the Center for
nternational Blood and Marrow Transplant Research
CIBMTR) to understand the effect of BMI on sur-
ival, relapse, and toxicity.
ETHODS
atabase
The CIBMTR is a voluntary working group of
ore than 373 transplant centers worldwide that con-
ribute detailed data on consecutive auto-HCTs to a
tatistical Center at the Health Policy Institute of the
edical College of Wisconsin in Milwaukee or the
ational Marrow Donor Program Coordinating Cen-
er in Minneapolis. Participating centers are required
o register all consecutive cases. The CIBMTR col-
ects data at 2 levels: registration and research. Regis-
ration data include disease type, age, sex, pretrans-
lantation performance status, disease stage and
hemotherapy responsiveness, date of diagnosis, do-
or and graft type (bone marrow–derived and/or
lood-derived stem cells), high-dose conditioning
egimen, posttransplantation engraftment, disease re-
urrence and survival, development of a new malig-
ancy, and cause of death. Requests for data on disease
r death for registered patients are at 6-month inter-
als. All CIBMTR teams contribute registration data
n all patients. Research data are collected on subsets
f registered patients selected by using a weighted
andomization scheme, including comprehensive pre-
ransplantation and posttransplantation clinical infor-
ation. Compliance is assessed by periodic audits, and p
42ccuracy of data is ensured by computerized record
hecks, physician review of submitted data, and on-
ite audits. Observational studies conducted by the
IBMTR are performed with a waiver of informed
onsent and in compliance with Health Insurance
ortability and Accountability Act regulations as de-
ermined by the Institutional Review Board and the
rivacy Ofﬁcer of the Medical College of Wisconsin.
atients
This study includes 4681 patients who underwent
uto-HCT from 1990 to 2000 for NHL or Hodgkin
ymphoma in 192 transplant centers. Patients were
ivided into groups by weight based on BMI. Weight
roups were deﬁned according to consensus weight
esignations by the World Health Organization [3]
nd the National Heart Lung and Blood Institute
xpert Panel [37] as follows: underweight, BMI 18
g/m2 (n  121); normal, BMI 18 to 25 kg/m2 (n 
909); overweight, BMI 25 to 30 kg/m2 (n  1725);
nd obese, BMI 30 kg/m2 (n  926). A total of
2 221 patients with NHL were registered with the
IBMTR during the study period, of which 4681
atients had research data (see above for distinction)
nd were included in the study. To ensure that the
esearch patients were representative of all registered
atients, demographics and relapse and survival rates
etween research and registered patients were com-
ared; no differences were noted. Median follow-up
as not statistically different across the weight groups,
ith a combined median follow-up of 44 months
range, 2-147 months) and a completeness of fol-
ow-up index [38] of 88%.
tudy End Points
Primary end points were transplantation-related
ortality (TRM), relapse, lymphoma-free survival
LFS), and overall survival. TRM was deﬁned as death
ithin the ﬁrst 28 days of transplantation from any
ause or death in continuous complete remission at
ny subsequent time point. Relapse was deﬁned as the
ime to onset of clinical recurrence, disease progres-
ion, or persistent disease. For relapse, patients with
ersistent disease were considered events at day 28.
FS was deﬁned as survival in continuous complete
emission of primary disease; disease relapse, persis-
ence, or death were events. Overall survival was de-
ned as time to death from any cause.
Secondary end points studied were the incidence
f infection, organ toxicity, secondary malignancies,
nd median days of hospitalization. Infections were
ivided into bacterial, viral, fungal, mixed, and other.
ung toxicity was divided into interstitial pneumoni-
is, adult respiratory distress syndrome, bronchiolitis
bliterans, pulmonary hemorrhage, and other. He-
atic toxicity was assessed from patient’s maximum
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BMI and Outcomes after Auto-HCT
Botal bilirubin level and the presence or absence of
eno-occlusive disease. Other types of organ dysfunc-
ion included were renal failure requiring dialysis,
hrombotic thrombocytopenia purpura/hemolytic ure-
ic syndrome, hemorrhagic cystitis, avascular necrosis,
nd other. New malignancies were categorized as clonal
ytogenetic abnormalities without leukemia, acute
yelogenous leukemia, other leukemias, myelodys-
lasia, lymphoma other than original histology, and
ther.
tatistical Analysis
Patient-, disease-, and transplant-related factors
ere compared among the 4 weight groups by using
he 2 test for categorical variables and the Kruskal-
allis test for continuous variables. Univariate prob-
bilities of LFS and overall survival were estimated by
sing the Kaplan-Meier method, whereas TRM and
elapse were estimated by using cumulative incidence
o allow for competing risks. Multivariate analyses
sed Cox proportional hazards regression models. Mod-
ls were constructed to compare the outcomes among
he 4 weight groups, with normal BMI used as the
aseline group, while adjusting for all covariates listed in
able 1. Information on the patient’s International
rognostic Index (IPI) at the time of diagnosis was not
vailable. However, with 27% of data missing, limited
nformation is available regarding IPI at transplanta-
ion (Table 2). A model was built for each primary
utcome of interest as a dependent variable and all the
elevant exposure variables as explanatory variables.
able 1. Variables Tested in the Multivariate Models
atient related
Age: <40 vs. >40 yr
Sex: male vs. female
Karnofsky status at transplantation: <90% vs. >90%-100%
Ethnicity: white vs. other
isease related
Lymphoma histology: low-grade NHL vs. intermediate NHL
vs. high-grade NHL vs. Hodgkin disease
Disease stage at diagnosis: stage I-II vs. stage III-IV
Presence of B symptoms at diagnosis: yes vs. no
Increased lactate dehydrogenase: yes vs. no
Disease stage and chemosensitivity: first complete remission
vs. second complete remission vs. sensitive relapse/primary
induction failure vs. resistant relapse/primary induction
failure vs. untreated/unknown
Bone marrow involvement at diagnosis/transplantation: yes
vs. no
Interval from diagnosis to transplantation: <12 vs. >12 mo
ransplant related
Conditioning regimen: TBI-containing vs. no TBI
Use of growth factors within 7 d after transplantation: yes
vs. no
Graft type: marrow vs. peripheral blood stem cells or both
Purging: yes vs. no
Year of transplantation: 1990-1992 vs. 1993-1995 vs. 1996-
1998 vs. 1999-2000o
Prior involved-field radiation: yes vs. no
B&MTmain effect term for the 4 weight groups was forced
nto the model. The proportional hazards assumption
or all the variables was examined by using time-
arying covariates. Construction of stratiﬁed propor-
ional hazards models or time-dependent covariates
as performed whenever nonproportional hazards
ere identiﬁed. Interactions between weight groups
nd other signiﬁcant explanatory variables were ex-
lored. Bonferroni corrections were applied to allow
djustment for multiple pairwise comparisons among
eight groups. A P value .02 was therefore consid-
red statistically signiﬁcant, whereas the P values for
nclusion in the ﬁnal models of all other potentially
onfounding covariates was set at .05. Comparisons
f all secondary outcomes were limited to univariate
omparisons.
ESULTS
atient Characteristics
Comparisons of patient-, disease-, and transplant-
elated characteristics among the weight groups are
isted in Table 2. No differences among the groups
ere observed with respect to disease stage at diagno-
is, marrow involvement at transplantation, the inter-
al from diagnosis to transplantation, remission status
nd chemosensitivity at transplantation, the use of
eld irradiation, the type of graft source, or median
ollow-up of survivors. The underweight group dif-
ered from the other groups in that they were younger
nd were more likely to be female and nonwhite and
o have poor performance status and a higher IPI
core at transplantation. They were less likely to have
tage III/IV disease at diagnosis but more likely to
ave “B” symptoms. They were less likely to have
eceived total body irradiation or a purged cell prod-
ct. The overweight and obese groups tended to be
omewhat older, were more likely to be male, and
ere more likely to have low-grade histologic charac-
eristics.
ransplantation-Related Mortality
There were no statistically signiﬁcant differences
n the cumulative incidence of TRM at 100 days after
ransplantation among the normal, overweight, and
bese groups (normal: 4%; 95% conﬁdence interval
CI], 3%-5%; overweight: 4%; 95% CI, 3%-5%;
bese: 4%; 95% CI, 3%-6%). However, the cumula-
ive incidence of TRM was signiﬁcantly higher in the
nderweight group, at 12% (95% CI, 6%-17%), at
00 days. This difference persisted (Figure 1). At 60
onths after transplantation, the cumulative inci-
ence rates of TRM were 10% (95% CI, 8%-11%) in
he normal-weight group, 9% (95% CI, 8%-11%) in
he overweight group, 10% (95% CI, 8%-12%) in the
bese group, and 20% (95% CI, 12%-28%) in the
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5able 2. Patient Characteristics
Variables Normal Weight Underweight Overweight Obese P Value
1909 121 1725 926
edian age, y (range) 42 (18-73) 34 (18-67) 47 (18-75) 46 (18-76) <.0001
<40 y, n (%) 898 (47) 73 (60) 564 (33) 312 (34) <.0001
>40 y, n (%) 1011 (53) 48 (40) 1161 (67) 614 (66)
ales 970 (51) 44 (36) 1199 (70) 578 (62) <.0001
nternational Prognostic Index at transplantation* .01†
Low 1038 (75) 57 (63) 957 (76) 511 (77)
Low-intermediate 236 (17) 20 (22) 214 (17) 110 (17)
High-intermediate 88 (6) 9 (10) 83 (6) 31 (5)
High 22 (2) 5 (5) 13 (1) 6 (1)
Missing 525 30 458 268
arnofsky performance status at transplantation >90% 1226 (64) 60 (50) 1162 (67) 667 (72) <.0001
ace
White 1633 (86) 91 (75) 1505 (87) 786 (85) .002
Others 276 (14) 30 (25) 220 (13) 140 (15)
istology‡
Low-grade NHL 273 (14) 7 (6) 330 (19) 188 (20) <.0001
Intermediate-grade NHL 794 (42) 46 (38) 763 (44) 417 (45)
High-grade NHL 224 (12) 20 (17) 196 (11) 97 (11)
Hodgkin disease 618 (32) 48 (39) 436 (26) 224 (24)
resence of B symptoms 844 (44) 65 (54) 698 (40) 349 (38) .0002
ncreased LDH 545 (29) 38 (31) 508 (29) 320 (35) .01
tage III-IV 1244 (65) 68 (56) 1149 (67) 610 (66) .13
one marrow involvement at diagnosis 379 (20) 16 (13) 418 (24) 198 (21) .001
one marrow involvement at transplantation 161 (8) 8 (7) 161 (9) 60 (7) .08
nterval from diagnosis to transplantation, n (%)
<12 mo 607 (32) 30 (25) 497 (29) 261 (28) .07
>12 mo 1302 (68) 91 (75) 1228 (71) 665 (72)
isease stage and chemosensitivity
CR1 248 (13) 17 (14) 209 (12) 115 (12) .46
CR2 343 (18) 19 (16) 321 (19) 174 (19)
Relapse/PIF sensitive 822 (43) 46 (38) 781 (45) 425 (46)
Relapse/PIF resistant 226 (12) 16 (13) 172 (10) 98 (11)
Untreated/unknown 270 (14) 23 (19) 242 (14) 114 (12)
se of TBI for conditioning 408 (21) 16 (13) 393 (23) 243 (26) .002
se of other field radiation 90 (5) 6 (5) 62 (4) 42 (5) .37
ype of graft
Bone marrow 573 (30) 37 (30) 477 (28) 251 (27) .28
Peripheral blood 1126 (59) 72 (60) 1080 (63) 566 (61)
Both 210 (11) 12 (10) 168 (9) 109 (12)
se of growth factors within 7 d after transplantation 1288 (67) 81 (67) 1216 (70) 678 (73) .01
urged 155 (8) 4 (3) 176 (10) 95 (10) .01
ear of transplantation
1990-1992 378 (20) 31 (25) 290 (17) 136 (15) .001
1993-1995 670 (35) 42 (35) 587 (34) 319 (34)
1996-1997 467 (24) 24 (20) 438 (25) 224 (24)
1998-2000 394 (21) 24 (20) 410 (24) 247 (27)
edian follow-up of survivors, mo (range) 44 (2-147) 48 (2-126) 44 (2-146) 44 (2-135) .52
HL indicates non-Hodgkin lymphoma; CR, complete remission; PIF, primary induction failure; LDH, lactate dehydrogenase; TBI, total
body irradiation.
Five adverse prognostic factors were considered: Age 60 years, Eastern Cooperative Oncology Group 2 (equivalent to Karnofsky score
before transplantation of 70), extranodal involvement of 1 site, stage III/IV, and LDH concentrations above normal.
ne point was given for each of the above characteristics present in the patient:
Risk Group IPI Scores
Low 0 or 1
Low-Intermediate 2
High-Intermediate 3
High 4 or 5
Other signiﬁcant 2 comparisons: P12  .01; P23  .001; P24  .001.
Low-grade NHL  small cell lymphocytic, follicular predominantly small cleaved, follicular mixed, small cleaved and large cell, and small
lymphocytic plasmacytoid; intermediate grade NHL  follicular predominantly large cell, diffuse small cleaved, diffuse mixed, small and
large cell, diffuse large cell, and large cell immunoblastic; high-grade NHL  lymphoblastic, small noncleaved unclassiﬁed, Burkitt,
non-Burkitt, primary mediastinal large B-cell, and precursor T-lymphoblastic.
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BMI and Outcomes after Auto-HCT
Bnderweight group. In multivariate analysis of TRM
Table 3), by using normal-weight patients as the
eference, the underweight group had a higher risk of
RM (relative risk [RR], 2.45; 95% CI, 1.58-3.81;
 .0001). Risks of TRM in the normal, overweight,
nd obese groups were similar. Other factors associ-
ted with an increased risk of TRM included age 40
ears at transplantation, Karnofsky performance status
KPS) 80% at transplantation, lymphoma histology
ther than low grade, chemoresistant disease at trans-
lantation, increased lactate dehydrogenase levels at
ransplantation, use of total body irradiation as part of
he preparative regimen, treatment of the graft to
educe malignant cell contamination, and time inter-
al 12 months from diagnosis to transplantation.
elapse
The cumulative incidence of relapse did not differ
igniﬁcantly among the 4 weight groups. The cumu-
ative incidences of relapse at 1 year after transplan-
ation were 44% (95% CI, 41%-46%) in the normal-
eight group, 43% (95% CI, 34%-53%) in the
nderweight group, 40% (95% CI, 38%-43%) in the
verweight group, and 38% (95% CI, 35%-42%) in
he obese group (Figure 2). Similarly, in multivariate
nalysis, no differences of relapse risk were observed.
actors associated with higher risks of relapse were
ge40 years at transplantation, KPS80% at trans-
lantation, disease stage other than ﬁrst complete re-
ission at transplantation, and marrow involvement at
ransplantation (data not shown).
ymphoma-Free Survival
Figure 3 shows Kaplan-Meier estimates of the
robabilities of LFS. LFS was signiﬁcantly lower in
he underweight group. One-year LFS probabilities
ere 41% (95% CI, 32%-50%), 50% (95% CI, 47%-
2%), 54% (95% CI, 52%-56%), and 54% (95% CI,
1%-57%) for the underweight, normal, overweight,
nd obese cohorts, respectively. Corresponding prob-
bilities at 5 years were 24% (95% CI, 15%-32%),
2% (95% CI, 30%-35%), 33% (95% CI, 30%-36%),
igure 1. Cumulative incidence of transplantation-related mortal-
ty (TRM) according to body mass index.nd 32% (95% CI, 29%-36%). In multivariate anal- §
B&MTsis (Table 4), with normal-weight patients as the
eference, the underweight group had a higher risk
f treatment failure (inverse of LFS; RR, 1.37; 95%
I, 1.11-1.71; P  .004), and the overweight group
ad a lower risk (RR, 0.91; 95% CI, 0.83-0.98; P 
02). The risks in the normal-weight and obese
roups were similar (RR, 0.91; 95% CI, 0.83-1.01;
 .08). Other factors associated with treatment
ailure were age 40 years at transplantation, KPS
80% at transplantation, disease stage and chemo-
ensitivity at transplantation, and the presence of B
ymptoms.
able 3. Multivariate Analysis of Transplantation-Related Mortality
TRM)
Variable
Relative Risk
of TRM P Value
ormal BMI* 1.00 <.0001†
nderweight BMI 2.45 (1.58-3.81) <.0001
verweight BMI 0.88 (0.70-1.09) .24
bese BMI 0.93 (0.72-1.21) .58
ther significant covariates
Age
<40 y 1.00
>40 y 1.69 (1.33-2.15) <.0001
Karnofsky performance status at
transplantation
90%-100% 1.00
<80% 1.50 (1.23-1.84) <.0001
Histologic type <.0001†
Low-grade NHL 1.00
Intermediate-grade NHL 1.95 (1.45-2.62) <.0001
High-grade NHL 1.61 (1.06-2.45) .02
Hodgkin disease 2.15 (1.51-3.06) <.0001
Disease stage and
chemosensitivity at
transplantation .009‡
CR1 1.00
CR2 1.17 (0.80-1.70) .42
Relapse/PIF, sensitive 1.06 (0.75-1.49) .75
Relapse/PIF, resistant 1.65 (1.09-2.49) .02
Untreated/unknown 1.52 (1.04-2.23) .03
LDH levels at diagnosis .01§
Normal 1.00
Increased 1.33 (1.07-1.64) .01
Missing 1.41 (1.04-1.91) .03
Use of TBI
No 1.00
Yes 1.40 (1.11-1.76) .004
Use of purging
No 1.00
Yes 1.89 (1.42-2.53) <.0001
Interval from diagnosis to
transplantation
<12 mo 1.00
>12 mo 1.81 (1.39-2.35) <.0001
MI indicates body mass index; NHL, non-Hodgkin lymphoma;
CR, complete remission; PIF, primary induction failure; LDH,
lactate dehydrogenase; TBI, total body irradiation.
Normal body mass index used as reference or baseline group.
Three degrees of freedom test.
Four degrees of freedom test.
Two degrees of freedom test.
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5verall Survival
Figure 4 shows Kaplan-Meier estimates of overall
urvival by weight group. Probabilities of survival
ere higher in the overweight and obese groups and
ower in the underweight group compared with the
ormal-weight cohort. One-year survival probabilities
ere 59% (95% CI, 50%-68%), 69% (95% CI, 67%-
1%), 74% (95% CI, 72%-76%), and 75% (95% CI,
2%-78%) in the underweight, normal, overweight, and
bese cohorts, respectively. Corresponding probabilities
t 5 years were 34% (95% CI, 25%-44%), 46% (95%
I, 44%-49%), 49% (95% CI, 46%-52%), and 56%
95% CI, 52%-59%). In multivariate analysis (Table 5),
ith normal-weight patients as the reference, the un-
erweight group had a higher risk of mortality (RR,
.49; 95% CI, 1.17-1.89; P  .001), whereas both the
verweight and obese groups had lower risks of mor-
ality (RR, 0.87; 95% CI, 0.79-0.96; P  .004 for the
verweight cohort; RR, 0.76; 95% CI, 0.67-0.86;
 .0001 for the obese cohort). Other factors
ssociated with higher risks of mortality were age
40 years at transplantation, KPS 80% at trans-
lantation, disease stage at transplantation other
han ﬁrst complete remission, presence of B symp-
oms, and transplantation in the early 1990s (com-
ared with the later 1990s).
oxicity
Posttransplantation toxicities are summarized in Ta-
le 6. There were no differences in maximum bilirubin
igure 2. Cumulative incidence of relapse according to body mass
ndex.
igure 3. Kaplan-Meier probability estimates of lymphoma-free
urvival (LFS) according to body mass index. a
46evels or in the incidence of infections, nonpulmonary/
onhepatic organ impairment, or new malignancies
mong the 4 weight groups. Pulmonary toxicity was
ore common in the underweight group (33% inci-
ence versus 19%-22% in the other 3 groups; P .002).
iver toxicity, including veno-occlusive disease, was
arginally higher in the underweight group as well
18% versus 11%-13%; P  .03). The median hospital-
zation stays were slightly longer in the underweight
igure 4. Kaplan-Meier probability estimates of overall survival
able 4. Multivariate Analysis of Lymphoma-Free Survival*
Variable
Relative Risk of
Treatment
Failure P Value
ormal BMI† 1.00 <.001‡
nderweight BMI 1.37 (1.11-1.71) .004
verweight BMI 0.91 (0.83-0.98) .02
bese BMI 0.91 (0.83-1.01) .08
ther significant covariates
Age
<40 y 1.00
>40 y 1.23 (1.13-1.34) <.0001
Karnofsky performance status at
transplantation
90%-100% 1.00
<80% 1.27 (1.18-1.38) <.0001
Disease stage and
chemosensitivity at
transplantation <.0001§
CR1 1.00
CR2 1.43 (1.23-1.68) <.0001
Relapse/PIF, sensitive 1.98 (1.73-2.27) <.0001
Relapse/PIF, resistant 3.15 (2.68-3.70) <.0001
Untreated/unknown 2.00 (1.71-2.34) <.0001
Presence of B symptoms .007
No 1.00
Yes 1.13 (1.04-1.22) .002
Missing 1.11 (0.95-1.29) .19
MI indicates body mass index; CR, complete remission; PIF,
primary induction failure.
Model stratiﬁed by histology and lactate dehydrogenase levels due
to nonproportional hazards.
Normal body mass index used as reference or baseline group.
Three degrees of freedom test.
Four degrees of freedom test.
Two degrees of freedom test.ccording to body mass index.
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BMI and Outcomes after Auto-HCT
Broup, at 23 days, versus 21 days for the other 3 groups
P  .03).
ISCUSSION
With respect to TRM, relapse, LFS and, most
mportantly, overall survival, outcomes after auto-
CT for lymphoma are at least equivalent for over-
eight and obese patients compared with normal-weight
ndividuals. The better overall survival experienced by
he overweight and obese patients compared with nor-
al-weight patients seems to reﬂect a combination of
lightly decreased relapse and TRM rates.
Our analysis is limited by the lack of data regard-
ng weight-based dose adjustment of chemotherapy.
osing schemes for preparative chemotherapy regi-
ens are quite variable across transplant centers. Cen-
ers differ in their use of ideal body weight, actual
ody weight, or compensatory calculations that yield
oses between actual and ideal weight [31]. Despite
able 5. Multivariate Analysis of Mortality*
Variable
Relative Risk of
Mortality P Value
ormal BMI† 1.00 <.0001‡
nderweight BMI 1.49 (1.17-1.89) .001
verweight BMI 0.87 (0.79-0.96) .004
bese BMI 0.76 (0.67-0.86) <.0001
ther significant covariates
Age
<40 y 1.00
>40 y 1.39 (1.25-2.54) <.0001
Karnofsky performance status at
transplantation
90%-100% 1.00
<80% 1.48 (1.35-1.61) <.0001
Disease stage and
chemosensitivity at
transplantation <.0001§
CR1 1.00
CR2 1.60 (1.32-1.93) <.0001
Relapse/PIF, sensitive 1.81 (1.53-2.14) <.0001
Relapse/PIF, resistant 3.35 (2.77-4.04) <.0001
Untreated/unknown 2.12 (1.75-2.56) <.0001
Presence of B symptoms <.0001
No 1.00
Yes 1.22 (1.12-1.33) <.0001
Missing 1.10 (0.92-1.32) .28
Year of transplantation .0003‡
1990-1992 1.00
1993-1995 0.88 (0.78-0.98) .02
1996-1997 0.84 (0.74-0.95) .01
1998-2000 0.73 (0.63-0.84) <.0001
MI indicates body mass index; CR, complete remission; PIF,
primary induction failure.
Model stratiﬁed by histology and lactate dehydrogenase levels due
to nonproportional hazards.
Normal body mass index used as reference or baseline group.
Three degrees of freedom test.
Four degrees of freedom test.
Two degrees of freedom test.his variability in dosing, toxicity seems equivalent c
B&MTmong the normal, overweight, and obese patients for
he variables tested, as does the median length of
ospitalization, thus implying that the overweight and
bese patients do not experience increased transplan-
ation-related complications. One possibility is that
verweight and obese patients may be receiving a
igher effective chemotherapy dose in the preparative
egimen without concomitantly increased toxicity.
rospective pharmacokinetic studies to elucidate lev-
ls of chemotherapeutics will be required to better
nderstand the correlation between effective dose and
utcomes. Alternatively, obese and overweight pa-
ients may have had better-prognosis disease at the
utset and were destined to fare better. We cannot
ssess the degree to which selection bias affects our
ndings. It is possible that sicker obese patients were
xcluded when comparably ill normal-weight patients
ere not. Also, there were modestly larger numbers of
ow-grade lymphomas in the obese and overweight
roups and fewer Hodgkin lymphomas. Nevertheless,
n multivariate analysis, these differences did not seem
o explain the observed outcomes. Another, less likely,
ossibility is that the disease in obese or overweight
atients is more sensitive to treatment; however, there
re no data to suggest that this is true, and the re-
orted pretransplantation chemosensitivity was not
ifferent across weight groups.
Previous single-institution studies have demon-
trated a signiﬁcant disadvantage for overweight and
bese patients. Tarella et al. [35] reported outcomes
or 121 patients receiving autografts for NHL, 28 of
hom had a BMI 28 kg/m2. In that study, 5 of 28
verweight/obese patients never received an autograft;
of the remaining 23 patients had unspeciﬁed dose
eductions that may have affected lymphoma-free and
verall survival. As in this study, there was no differ-
nce in the TRM. In a retrospective study by Meloni
t al. [39] that examined outcomes in 54 patients
eceiving autografts for acute myeloid leukemia, 9 of
hom were obese, there was a signiﬁcant difference in
RM. In that study, patients did not receive dose
djustments on the basis of overweight. Conversely, a
tudy from the Fred Hutchinson Cancer Research
enter retrospectively reviewed outcomes in their
arge series of allografts and autografts and found no
igniﬁcant survival disadvantage to overweight overall
36]. When Fred Hutchinson Cancer Research Center
esults only for allografts for chronic myeloid leuke-
ia were reviewed by Hansen et al. [40], there was a
light survival disadvantage for the overweight/obese
atients; this suggests that when disease factors such as
elapse are less problematic, then mildly adverse ef-
ects of overweight can be discerned. Although there
as been previous work showing conclusions opposite
rom this analysis, no prior study has been able to
nclude such large patient numbers from multiple
enters.
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5Adding credibility to these results is the dose-
esponse relationship between BMI and overall sur-
ival. The underweight group had the worst survival,
he normal-weight group had the third best, then the
verweight group, and ﬁnally the obese group, which
ad the highest overall survival. This surprising result
ontradicts the conventional wisdom that as weight
ncreases, outcomes worsen. Recent data published by
legal et al. [41] examining the effects of overweight
able 6. Toxicities
Variable
Underweig
(n  121)
nfection (%)
No 45 (3)
Yes 76 (63%)
ype of infection (%)
Bacterial 27 (36)
Fungal 7 (9)
Viral 11 (14)
Mixed 23 (30)
Others 8 (11)
ulmonary (%)
No 81 (67)
Yes 40 (33)
ype of pulmonary abnormality (%)
Interstitial pneumonitis 13 (33)
ARDS 6 (15)
Bronchiolitis obliterans 1 (2)
Pulmonary hemorrhage 4 (10)
Others 23 (57)
aximum bilirubin level, mg/dL, median (range) 1.10 (0.4-2
iver toxicity (%) 14
No 99 (82)
Yes 22 (18)
VOD* 11 (50)
rgan impairment (%)
No 90 (74)
Yes 31 (26)
ype of organ impairment (%)
Renal failure requiring dialysis 5 (16)
TTP/HUS 1 (3)
Hemolytic cystitis 6 (19)
Avascular necrosis —
Others 20 (65)
ew malignancies (%)
No 117 (97)
Yes 4 (3)
ypes (%)
Clonal cytogenetic abnormality without
leukemia or MDS —
AML —
Other leukemia —
Myelodysplasia 1 (25)
Lymphoma —
Other cancer 3 (75)
edian hospitalization, d, median (range) 23 (3-60)
21
RDS indicates adult respiratory distress syndrome; VOD, veno
myelodysplasia; HUS, hemolytic uremic syndrome; AML, acute
Represents the number of cases with liver toxicity manifesting asnd obesity on mortality rates of the American popu- w
48ation as a whole also suggested no increase in mor-
ality for those who were overweight (BMI 25 to 30
g/m2). This same phenomenon may be at least in
art reﬂected in this study.
Another important ﬁnding of this study is the
onﬁrmation of prior investigations suggesting that
nderweight patients have higher transplantation-re-
ated mortality (TRM) and poorer lymphoma-free and
verall survival than normal-weight, obese, or over-
Normal Weight
(n  1909)
Overweight
(n  1725)
Obese
(n  926)
P
Value
.311
848 (44) 758 (44) 389 (42)
1061 (56) 967 (56) 537 (58)
390 (37) 387 (40) 232 (43)
67 (6) 63 (7) 30 (6)
88 (8) 100 (10) 38 (7)
349 (33) 260 (27) 171 (32)
167 (16) 157 (16) 66 (12)
.002
1489 (78) 1391 (81) 741 (80)
420 (22) 334 (19) 185 (20)
139 (33) 113 (34) 50 (27)
49 (12) 40 (12) 28 (15)
3 (1) 2 (1) 3 (2)
26 (6) 21 (6) 10 (5)
263 (63) 204 (61) 123 (66)
1.05 (0.4-36) 1.10 (0.4-36) 1.10 (0.4-32) .717
206 176 85 .030
1653 (87) 1524 (88) 827 (89)
256 (13) 201 (12) 99 (11)
71 (28) 49 (24) 26 (26)
.433
1454 (76) 1296 (75) 679 (73)
455 (24) 429 (25) 247 (27)
43 (9) 37 (9) 27 (11)
10 (2) 5 (1) —
26 (6) 43 (10) 22 (9)
6 (1) 3 (1) 3 (1)
378 (83) 344 (80) 200 (81)
.655
1837 (96) 1643 (95) 887 (96)
72 (4) 82 (5) 39 (4)
2 (3) 2 (2) 2 (5)
4 (6) 6 (7) 3 (8)
2 (3) 5 (6) 1 (2)
22 (30) 22 (27) 9 (23)
1 (1) 3 (4) 1 (2)
41 (57) 44 (54) 23 (60)
21 (1-60) 21 (1-60) 21 (1-60) .034
187 159 81
ive disease; TTP, thrombotic thrombocytopenia purpura; MDS,
genous leukemia.ht
6)
-occlus
myeloeight patients. This observation has been made not
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BMI and Outcomes after Auto-HCT
Bnly in HCT, but also in general population studies
42,43] and in surgical [21,44] and critical care [45]
renas. There are several possible explanations. The
nderweight group may have limited nutritional re-
erves and, therefore, lower tolerance to the stresses of
uto-HCT, thus resulting in a higher rate of TRM.
nfortunately, no information is available regarding
he patterns of use of parenteral nutritional support
ecause the CIBMTR does not collect data regarding
otal parenteral nutrition use during transplantation.
ower BMI may reﬂect the presence of more aggres-
ive disease causing a greater degree of physiologic
erangement. However, although there seems to be a
ifference in disease severity (the underweight group
anifested a higher IPI score at transplantation com-
ared with the other groups), this did not result in a
tatistically higher rate of relapse. Finally, comorbid
onditions may lead to both weight loss and an in-
reased transplantation risk. It is not possible to easily
scertain which of these factors is playing a role, but
he data suggest that disease-related factors are less
ikely to be the explanation, because relapse rates were
ot higher in the underweight patients.
As with any observational study, it is possible that
atient selection bias may inﬂuence these ﬁndings.
ata are not available for patient groups who did not
ndergo transplantation. It is conceivable that only
atients believed by the transplant center to be sufﬁ-
iently ﬁt proceeded to transplantation, whereas more
ll obese patients were excluded. However, there are
ubstantial numbers of patients in the overweight or
bese groups, thus suggesting that this is not a group
f highly selected patients. Moreover, a review of co-
orbidities showed a statistically signiﬁcantly increa-
ed incidence of coronary artery disease, hypertension,
iabetes, and thyroid disease among the overweight
nd obese groups compared with normal-weight patients
data not shown). This ﬁnding suggests that the expected
besity-related illnesses were in fact observed, although
hether the frequency of comorbidities observed re-
ects the expected incidence in the overweight and
bese population as a whole is not known. The pro-
ortions of patients in the respective weight groups
re as follows: normal, 40.7%; overweight, 36.9%;
bese, 19.8%; and underweight, 2.6%. These propor-
ions are reﬂective of weight distribution in the
nited States [46], although it cannot be known
hether this proportion is reﬂective of the BMI dis-
ribution of lymphoma patients who are candidates for
uto-HCT.
In conclusion, our study indicates that overweight
nd obese patients receiving auto-HCT for lymphoma
o not experience inferior outcomes compared with
ormal-weight patients. Consideration of these patients
or auto-HCT should not be adversely inﬂuenced by
besity alone. Conversely, for the underweight group,
utcomes are signiﬁcantly worse. Perhaps most notably, o
B&MTRM seems to be markedly increased, thus suggesting
hat these patients may require more than standard levels
f support. Studies of interventions to improve the nu-
ritional status of low-BMI patients before and after
ransplantation may be warranted. These ﬁndings need
o be conﬁrmed in a well-designed prospective trial,
erhaps in a cooperative group setting.
Previous studies documenting negative physician
ttitudes toward obese patients suggest that there may
e prejudice in the decision-making and treatment
rocesses. We hope that this study helps to dispel the
elief that overweight or obese patients, when other-
ise ﬁt and qualiﬁed, cannot be treated as effectively
r safely as normal-weight patients.
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